Dyne hits four-month high as Guggenheim starts with Buy

Jan. 26, 2023 12:29 PM ETDyne Therapeutics, Inc. (DYN)RNABy: Dulan Lokuwithana, SA News Editor

Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

  • The shares of Dyne Therapeutics (NASDAQ:DYN) reached the highest level since September on Thursday as Guggenheim launched its coverage with a Buy rating and a $33 price target citing the biotech’s potential in muscular diseases.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.